Steve Schonfeld’s Allogene Therapeutics ALLO Stock Holding History

Steve Schonfeld’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$110K	Buy	+53,079	New	+$117K	﹤0.01%	2294
2024 Q3	–	Sell	-17,192	Closed	-$40.1K	–	2010
2024 Q2	$40.1K	Buy	+17,192	New	+$50.7K	﹤0.01%	1955
2024 Q1	–	Sell	-35,300	Closed	-$113K	–	2036
2023 Q4	$113K	Buy	+35,300	New	+$100K	﹤0.01%	1607
2023 Q3	–	Sell	-102,285	Closed	-$508K	–	1741
2023 Q2	$508K	Buy	+102,285	New	+$553K	﹤0.01%	1219
2023 Q1	–	Sell	-124,500	Closed	-$783K	–	2064
2022 Q4	$783K	Sell	124,500 -139,391	-53%	-$1.29M	0.01%	1278
2022 Q3	$2.85M	Buy	263,891 +145,491	+123%	+$1.98M	0.02%	730
2022 Q2	$1.35M	Buy	118,400 +38,000	+47%	+$337K	0.01%	881
2022 Q1	$732K	Buy	+80,400	New	+$837K	0.01%	1148
2021 Q4	–	Sell	-40,500	Closed	-$1.04M	–	2107
2021 Q3	$1.04M	Sell	40,500 -63,779	-61%	-$1.51M	0.01%	935
2021 Q2	$2.72M	Buy	+104,279	New	+$2.97M	0.03%	623
2019 Q1	–	Sell	-10,000	Closed	-$269K	–	1035
2018 Q4	$269K	Buy	+10,000	New	+$266K	0.01%	857

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Steve Schonfeld's ALLO Position: Q2 2026 in Review

Steve Schonfeld opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 53,079 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #2294 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in ALLO as recently as Q2 2024.

Steve Schonfeld first reported a position in ALLO in Q4 2018 and has held it in 11 quarters since. The position peaked at $2.85M in Q3 2022. 207 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Steve Schonfeld held 53,079 shares of Allogene Therapeutics worth $110K as of Q2 2026.
Allogene Therapeutics was a new Steve Schonfeld position in Q2 2026.
Allogene Therapeutics made up ﹤0.01% of Steve Schonfeld's portfolio in Q2 2026, its #2294 holding.
Steve Schonfeld first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 11 quarters since.
Steve Schonfeld's Allogene Therapeutics position peaked at $2.85M in Q3 2022.
207 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.